Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) gapped down prior to trading on Monday after Morgan Stanley lowered their price target on the stock from $761.00 to $756.00. The stock had previously closed at $564.63, but opened at $551.50. Morgan Stanley currently has an overweight rating on the stock. Regeneron Pharmaceuticals shares last traded at $552.51, with a volume of 407,388 shares changing hands.

Several other equities analysts also recently issued reports on REGN. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a research note on Monday, August 4th. Canaccord Genuity Group reissued a “buy” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a research note on Friday, August 1st. Finally, Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $817.88.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 1.2%

The business’s 50 day moving average price is $573.67 and its 200-day moving average price is $563.46. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market cap of $59.11 billion, a price-to-earnings ratio of 14.06, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the firm posted $11.56 EPS. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.